This research focused on the development and assessment of Citicoline orally disintegrating. tablets (ODTs) utilizing a co-processed superdisintegrant composed of Isabgol mucilage and Crospovidone to facilitate swift tablet disintegration and drug dissolution. Isabgol mucilage was isolated from Isabgol husk and analyzed for its physicochemical properties. The isolated mucilage was co-processed with Crospovidone and evaluated for micrometric characteristics. Five distinct Citicoline ODT formulations (designated F1 through F5) were manufactured via direct compression using varying proportions of the co-processed superdisintegrant. These formulations underwent comprehensive evaluation, including pre-compression and post compression assessments, FTIR analysis for drug-excipient compatibility, wetting and disintegration time measurements, drug content determination, content uniformity testing, and in vitro dissolution profiles The isolated Isabgol mucilage yielded a recovery rate of 33% and demonstrated a swelling index of 310%. The micrometric evaluation of the co-processed superdisintegrant revealed an angle of repose of 26.42°, a Cam's Index of 14.28%, and a Hausner ratio of 1.16. Among the tested formulations, F5 displayed superior overall characteristics, featuring a mean weight of 399 mg, a hardness of 4 kg/cm’, friability of 0.12%, a wetting time of 16 seconds, a disintegration time of 17 seconds, and a drug content of 99.8%. Furthermore, formulation F5 achieved complete (100%) drug release within 30 minutes, with content uniformity maintained between 98.98% and 100.17%. This investigation confirms that the co-processed Isabgol mucilage—Crospovidone system serves as an efficient superdisintegrant for Citicoline ODTs. The optimized F5 formulation demonstrated rapid wetting and disintegration, adequate mechanical integrity, consistent drug distribution, and full drug release, highlighting its viability for the production of Citicoline orally disintegrating tablets.